Methylated CpG Plasmid Modulating Autoimmunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating immune-mediated inflammatory disorders, such as type 1 diabetes, are inefficient and can induce or enhance autoimmunity, with DNA-based vaccines and cytokine treatments having significant drawbacks.
Innovation Solution
A plasmid comprising a polynucleotide encoding an autoantigen or donor antigen under the control of a promoter, combined with a pro-apoptotic protein, and including CpG motifs, is used to modulate the immune response, inducing apoptosis and reducing autoimmunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DNA-based vaccines are used to prevent type 1 diabetes, then autoimmunity may be suppressed, but the vaccines are not completely efficient and can induce or enhance autoimmunity
Solution Approach 1:
The patent converts the harmful effect of CpG motifs (which can induce autoimmunity) into a beneficial effect by methylating them. The methylated CpG motifs lose their ability to induce autoimmunity while retaining their ability to stimulate regulatory T cells, thus transforming a harmful factor into a therapeutic agent.
Solution Approach 2:
The patent changes the chemical state of CpG motifs from unmethylated to methylated. This parameter change fundamentally alters their biological activity, transforming them from autoimmunity-inducing elements into regulatory T cell stimulators, thereby resolving the contradiction between effectiveness and harmful effects.
2Reliability
If cytokines are administered to suppress the immune system, then autoimmunity may be reduced, but significant morbidity occurs due to general immune suppression
Solution Approach 1:
Instead of using cytokines that cause general immune suppression (affecting the entire immune system), the patent uses methylated CpG motifs that specifically stimulate regulatory T cells. This creates a localized effect within the immune system, suppressing autoimmunity while preserving overall immune function and avoiding widespread morbidity.
Solution Approach 2:
The patent introduces regulatory T cells as an intermediary mechanism. Rather than directly suppressing the immune system with cytokines, the methylated CpG motifs activate regulatory T cells, which then mediate the suppression of pathogenic autoimmunity. This intermediary approach is more selective and avoids the harmful effects of direct immune suppression.
3Reliability
If daily insulin injection is used to treat type 1 diabetes, then insulin deficiency is addressed, but precise replacement of physiological levels is not achieved
Solution Approach 1:
The patent applies preliminary action by preventing the destruction of beta cells through the activation of regulatory T cells. By stopping the autoimmune attack before it destroys the insulin-producing cells, the natural insulin production can be preserved or restored, providing more precise replacement of physiological insulin levels compared to exogenous insulin injection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively delays the onset or treats immune-mediated inflammatory disorders by reducing antibody levels and improving insulin production, with fewer side effects compared to existing treatments.
Implementation Method 1
a polynucleotide encoding a pro-apoptotic protein under the control of a promoter capable of promoting the polynucleotide encoding the pro-apoptotic protein
Data Source
AI summary
A substance or a composition for preventing, delaying the onset of or treating one or more than one immune-mediated inflammatory disorder in an organism who is susceptible to developing the immune-mediated inflammatory disorder, who is developing the immune-mediated inflammatory disorder or who has the immune-mediated inflammatory disorder. A method of preventing, delaying the onset of or treating an organism who is susceptible to developing the immune-mediated inflammatory disorder, who is developing the immune-mediated inflammatory disorder or who has the immune-mediated inflammatory disorder.